Serum IL-22 binding protein as a marker for atopic dermatitis activity and response to dupilumab treatment

Clin Exp Allergy. 2022 Jun;52(6):820-823. doi: 10.1111/cea.14147. Epub 2022 May 10.

Authors

Cláudia Varandas^{1

2}, Maria Conceição Pereira-Santos¹, Marta Neto², Ana E Sousa¹, Anabela Lopes², Susana L Silva^{1

2}

Affiliations

¹ Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
² Serviço de Imunoalergologia, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

PMID: 35416344
DOI: 10.1111/cea.14147

No abstract available

Keywords: IL-22; IL-22 binding protein; anti-IL-4R therapy; atopic dermatitis.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized / therapeutic use
Biomarkers
Dermatitis, Atopic* / diagnosis
Dermatitis, Atopic* / drug therapy
Humans
Interleukin-22
Interleukins
Treatment Outcome

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Biomarkers
Interleukins
dupilumab